In the present study, we demonstrate that long-term treatment of the DPP-4 inhibitor vildagliptin in rats with LV remodeling due to MI increases endogenous active plasma GLP-1 levels, via inhibition of DPP-4 activity. Here, GCG is linked to myocardial infarction.